Alembic Pharmaceuticals Ltd revenue up by 8% to Rs. 1595 crores in Q-2 FY24

Telugu super news,Mumbai, November 7th, 2023: Alembic Pharmaceuticals Limited reported its consolidated financial results for the second quarter and half year ended 30th September, 2023.

Financial Highlights

·         Net Sales grew 8% to Rs.1595 crores for the quarter.

·         Net Profit for the quarter at Rs.137 crores.

·         Net Sales grew 13% to Rs.3081 crores for the H-1.

·         Net Profit for H-1 at Rs.257 crores.

Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited said “Despite the challenges of a muted demand in the Antibiotic and respiratory market, it was a satisfactory quarter, backed with a strong performance by our specialty and animal healthcare portfolio. We are confident of returning to an industry beating growth moving forward”.

Operational Highlights

India Branded Business

·         India Branded Business at INR 577 crores witnessed growth of 5% in Q2FY24 against IPM growth of 7%.

·         Specialty therapies recorded growth of 10%* vis a vis industry growth of 9%*.

·         Performed relatively better than the market in Antibiotic and Respiratory segments. Underlying factors remain strong despite muted demand in acute market for the quarter due to weak season.

·         Animal Health business recorded growth of 32% over PY Q2.

*IQVIA Qtr September’ 23

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said“It was a satisfactory quarter led by growth in all the verticals of the company, in particular Ex-US which grew by 17% and the API business outperformed with a 10% growth during the quarter

Operational Highlights

International Business

·         US Generics at Rs. 444 crores up by 6% on YoY basis and by 14% on QoQ basis

·         Ex-US International Formulations grew 17% to Rs. 252 Crores in the quarter.

·         We have regular exports now from both general injectable and oncology plants.

·         6 ANDA approvals received during the quarter; 190 Cumulative ANDA approvals.

·         2 ANDA filings during the quarter; Cumulative ANDA filings at 252.

API Business

·         API business grew 10% at Rs. 322 crores in the quarter.

·         132 cumulative DMF Filings.

The summary of Total Revenue is as under:    (Rs in Crores)

ParticularsQ2 FY24Q2 FY23% ChangeH-1 FY24H-1 FY23% Change
  India                            5775495%110110297%
  USA  Ex- US4442524182156%17%8345187853966%31%

Leave a Reply